X4 Pharmaceuticals (XFOR) Return on Equity (2018 - 2025)
Historic Return on Equity for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to 2.9%.
- X4 Pharmaceuticals' Return on Equity fell 26800.0% to 2.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.9%, marking a year-over-year decrease of 26800.0%. This contributed to the annual value of 1.02% for FY2024, which is 5900.0% up from last year.
- According to the latest figures from Q3 2025, X4 Pharmaceuticals' Return on Equity is 2.9%, which was down 26800.0% from 7.58% recorded in Q2 2025.
- In the past 5 years, X4 Pharmaceuticals' Return on Equity registered a high of 0.65% during Q1 2025, and its lowest value of 7.58% during Q2 2025.
- Over the past 5 years, X4 Pharmaceuticals' median Return on Equity value was 1.53% (recorded in 2023), while the average stood at 1.78%.
- Examining YoY changes over the last 5 years, X4 Pharmaceuticals' Return on Equity showed a top increase of 55900bps in 2025 and a maximum decrease of -79500bps in 2025.
- Quarter analysis of 5 years shows X4 Pharmaceuticals' Return on Equity stood at 1.33% in 2021, then fell by -4bps to 1.38% in 2022, then decreased by -23bps to 1.7% in 2023, then skyrocketed by 46bps to 0.92% in 2024, then crashed by -217bps to 2.9% in 2025.
- Its Return on Equity stands at 2.9% for Q3 2025, versus 7.58% for Q2 2025 and 0.65% for Q1 2025.